Higher circulating concentrations of 25-hydroxyvitamin D are associated with a lower risk of renal cell carcinoma (RCC), new data suggest.
The data are from a study in which investigators in China compared 135 newly diagnosed cases of RCC with 135 controls matched by age and sex. Average plasma levels of 25-hydroxyvitamin D [25 (OH) D] were significantly lower in the cases compared with controls (21.5 vs 24.1 ng/mL), Fei Li, MD, of Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China, and colleagues reported in the International Brazilian Journal of Urology. Compared with patients who had 25 (OH) D levels below 20 ng/mL (reference), those with levels of 20–29.9 ng/mL and 30 ng/mL or higher had a significant 50% and 70% decreased risk odds of RCC after adjusting for age, sex, body mass index, season of blood draw, hypertension, diabetes and history of smoking and alcohol consumption.
In addition, each 10 ng/mL increment in 25 (OH) D level was associated with a significant 13% decreased risk of RCC.
The cases and controls had mean ages of 52.3 and 53.7 years, respectively. The groups did not differ significantly with regard to smoking status, alcohol consumption, and presence of diabetes and hypertension. Of the cases and controls, 45.9% and 30.4% had vitamin D deficiency, which the investigators defined as 25 (OH) D levels below 20 ng/mL.
Li F, Zhao HF, Hou L, et al. A higher circulating concentration of 25-hydroxyvitamin-D decreases the risk of renal cell carcinoma: a case-control study. Int Braz J Urol. 2019; published online ahead of print.